Thelansis

Non-Tuberculous Mycobacterial (NTM) Emerging Therapy and TPP Insights Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Non-Tuberculous Mycobacterial (NTM) Overview Non-tuberculous mycobacterial (NTM) pulmonary disease is a chronic, progressive, and highly morbid respiratory infection caused by ubiquitous environmental mycobacteria, most predominantly the Mycobacterium avium complex (MAC) and the highly resistant Mycobacterium abscessus . The disease opportunistically exploits compromised structural lung architecture—most notably in patients with underlying bronchiectasis, cystic fibrosis, or chronic obstructive pulmonary disease (COPD)—driving relentless granulomatous inflammation and irr...

Non-Tuberculous Mycobacterial (NTM) Emerging Therapy and TPP Insights Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Ta...

Non-Tuberculous Mycobacterial (NTM) Market Outlook Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial (NTM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greates...

Non-Tuberculous Mycobacterial (NTM) Market Outlook Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial (NTM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Non-Tuberculous Mycobacterial (NTM) Overview Non-tuberculosis mycobacterial (NTM) lung infections, while less common than those caused by Mycobacterium tuberculosis, are transmitted via inhaled aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include close living quarters, coughing, and failure to wear masks. Advanced age, immunosuppression, and corticosteroid...

 Non-tuberculosis mycobacterial (NTM) lung infections, while less common than those caused by Mycobacterium tuberculosis, are transmitted via inhaled aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include close living quarters, coughing, and failure to wear masks. Advanced age, immunosuppression, and corticosteroid use raise the risk of acquiring NTM microorganisms. Once inside the body, NTM microorganisms primarily settle in the lower airways, leading to an inflammatory response characterized by an influx of lymphocytes. This immune reaction releases cytokines and other mediators, resulting in pneumonia-like symptoms, including fever, weight loss, night sweats, decreased appetite, and energy loss. The prognosis of NTM lung infections is uncertain, particularly for immunocompromised patients. The prognosis may also vary based on the specific NTM infection type. Research suggests that Mycobacterium avium complex (MAC) infections have a more ...

 Non-Tuberculous Mycobacterial (NTM) are bacteria that are normally present in the environment. Inhalation of these bacteria may cause disease in both healthy patients and those with compromised immune systems. NTM disease most often affects the lungs in adults, but it may also affect any body site. Chronic pulmonary disease is the most common localized clinical manifestation of NTM. Mycobacterium avium complex, followed by M. kansasii, is the most frequent pathogen causing lung disease in the United States. Other pathogens occasionally causing pulmonary disease include M. abscessus, M. fortuitum, M. szulgai, M. simiae, M xenopi, M. malmoense, M. celatum, M. asiaticum, and M. shimodii. Except for patients with cystic fibrosis, children rarely develop this form of NTM disease, Although some NTM patients have a history of underlying chronic lung disease. The interpretation of NTM in the sputum of HIV-positive patients presents a particular problem, as these patients are frequently in...